drugset / Trial / NCT03742245
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
Phase 1
Active not recruiting
28 enrolled
The Methodist Hospital Research Institute
AstraZeneca · collabMerck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to test the safety and preliminary efficacy of olaparib and vorinostat when used together in participants with relapsed/refractory and or metastatic breast cancer.
Timeline
- Start
- 2019-06-11
- Primary completion
- 2025-12-01
- Completion
- 2026-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Olaparib | Small molecule | 100 mg | Oral |
| Subject | Olaparib | Small molecule | 200 mg | Oral |
| Subject | Olaparib | Small molecule | 300 mg | Oral |
| Subject | Vorinostat | Small molecule | 300 mg | Oral |
| Subject | Vorinostat | Small molecule | 400 mg | Oral |